通过静脉内、肌肉内或皮下途径给予小鼠重组干扰素-β对小鼠肝炎病毒感染的保护作用。

Protective effects of murine recombinant interferon-beta administered by intravenous, intramuscular or subcutaneous route on mouse hepatitis virus infection.

作者信息

Matsuyama S, Henmi S, Ichihara N, Sone S, Kikuchi T, Ariga T, Taguchi F

机构信息

National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi, Kodaira, 187-8502, Tokyo, Japan.

出版信息

Antiviral Res. 2000 Aug;47(2):131-7. doi: 10.1016/s0166-3542(00)00097-8.

DOI:10.1016/s0166-3542(00)00097-8

PMID:10996401

Abstract

The significance of the route for administration of murine recombinant interferon-beta (IFN-beta) for inducing its therapeutic effects has been studied. BALB/c mice were daily injected intravenously, intramuscularly or subcutaneously with 1.5x10(3), 1. 5x10(4), or 1.5x10(5) IU of IFN-beta, from one day before to 8th day after mouse hepatitis virus (MHV-2) challenge. All mice received IFN-beta survived significantly longer than those without IFN. In the liver of those IFN-treated mice, viral growth and the histopathological damages were extremely alleviated. These results suggest that, irrespective of the differences in the route of administration, IFN-beta markedly suppressed viral activity when its administration was started prior to viral infection. For clinical use, however, further studies are needed on the optimal route for administration if IFN-beta is given after viral infection.

摘要

对小鼠重组干扰素-β（IFN-β）给药途径诱导其治疗效果的意义进行了研究。从感染小鼠肝炎病毒（MHV - 2）前一天至感染后第8天，每天给BALB/c小鼠静脉内、肌肉内或皮下注射1.5×10³、1.5×10⁴或1.5×10⁵国际单位的IFN-β。所有接受IFN-β治疗的小鼠存活时间明显长于未接受IFN治疗的小鼠。在这些接受IFN治疗的小鼠肝脏中，病毒生长和组织病理学损伤得到极大缓解。这些结果表明，无论给药途径有何差异，在病毒感染前开始给予IFN-β时，它都能显著抑制病毒活性。然而，对于临床应用而言，如果在病毒感染后给予IFN-β，还需要进一步研究最佳给药途径。